Entwicklung und klinische Anwendung neuartiger retroviraler Vektorsysteme fuer die somatische Gentherapie Abschlussbericht

Retroviral vectors for the singular expression of the receptor molecule LNGFR on hematopoietic cells for gene marking and also vectors for the co-expression of LNGFR and HSV TK were developed within this subproject at Boehringer Mannheim GmbH. GMP production and toxicology studies were performed, clinical protocols were established. The planned gene marking study was not performed as no new data in comparison to the literature were expected at that time. The LNGF/TK vectors for the induction of GvL effects in leukemia/lymphoma patients with allogeneic T cells and the treatment of GvHD induced by the allogeneic cells were fully developed for clinical use. Crucial data were produced for the establishment of the production of retroviral vectors in cells growing in suspension. Approaches utilizing the mdr-1 coding vectors for the protection of stem cells were not pursued because of considerable doubts with respect to safety and scientific rationale. (orig.)SIGLEAvailable from TIB Hannover: DtF QN1(72,33) / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekBundesministerium fuer Bildung, Wissenschaft, Forschung und Technologie, Bonn (Germany)DEGerman